enVVeno Medical Corp 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to ___________________ Commission file number: 001-38325 enVVeno Medical Corporation (Exact name of registrant as specified in its charter) Delaware 33-0936180 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 70 Doppler Irvine , California 92618 (Address of principal executive offices) (949) 261-2900 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class: Name of Each Exchange on Which Registered: Ticker Symbol Common Stock, $0.00001 par value Warrant to Purchase Commons Stock The NASDAQ Stock Market LLC The NASDAQ Stock Market LLC NVNO NVNOW Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ As of November 9, 2021, there were 9,468,324 shares of common stock outstanding. ENVVENO MEDICAL CORPORATION f/k/a HANCOCK JAFFE LABORATORIES, INC. TABLE OF CONTENTS PART I FINANCIAL INFORMATION ITEM 1. Financial Statements 1 Condensed Balance Sheets as of September 30, 2021 (Unaudited) and December 31, 2020 1 Unaudited Condensed Statements of Operations for the three and nine months ended September 30, 2021 and 2020 2 Unaudited Condensed Statements of Changes in Stockholders’ Equity (Deficiency) for the nine months ended September 30, 2021 and 2020 3 Unaudited Condensed Statements of Cash Flows for the nine months ended September 30, 2021 and 2020 4 Notes to Unaudited Condensed Financial Statements 6 ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 14 ITEM 3. Quantitative and Qualitative Disclosures About Market Risk 19 ITEM 4. Controls and Procedures 19 PART II OTHER INFORMATION 20 ITEM 1. Legal Proceedings 20 ITEM 1A. Risk Factors 20 ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 20 ITEM 3. Defaults Upon Senior Securities 20 ITEM 4. Mine Safety Disclosures 20 ITEM 5. Other Information 20 ITEM 6. Exhibits 21 Signatures 22 PART I – FINANCIAL INFORMATION ITEM 1 – Financial Statements ENVVENO MEDICAL CORPORATION f/k/a HANCOCK JAFFE LABORATORIES, INC. CONDENSED BALANCE SHEETS (Unaudited) September 30, December 31, 2021 2020 Assets Current Assets: Cash and cash equivalents $ 57,896,922 $ 9,334,584 Prepaid expenses and other current assets 310,046 234,467 Total Current Assets 58,206,968 9,569,051 Property and equipment, net 598,976 398,967 Operating lease right-of-use assets, net 311,790 539,974 Security deposits and other assets 54,493 29,843 Total Assets $ 59,172,227 $ 10,537,835 Liabilities and Stockholders’ Equity Current Liabilities: Accounts payable $ 394,191 $ 1,390,362 Accrued expenses and other current liabilities 358,644 1,135,969 Note Payable - 312,700 Deferred revenue - related party 33,000 33,000 Current portion of operating lease liabilities 332,297 314,202 Total Current Liabilities 1,118,132 3,186,233 Long-term operating lease liabilities - 253,746 Total Liabilities 1,118,132 3,439,979 Commitments and Contingencies - - Stockholders’ Equity: Preferred stock, par value $ 0.00001 , 10,000,000 shares authorized: no shares issued or outstanding - - Common stock, par value $ 0.00001 , 250,000,000 shares authorized, 9,468,324 and 2,541,529 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 95 25 Additional paid-in capital 130,917,501 72,421,242 Accumulated deficit ( 72,863,501 ) ( 65,323,411 ) Total Stockholders’ Equity 58,054,095 7,097,856 Total Liabilities and Stockholders’ Equity $ 59,172,227 $ 10,537,835 See Notes to these Unaudited Condensed Financial Statements 1 ENVVENO MEDICAL CORPORATION f/k/a HANCOCK JAFFE LABORATORIES, INC. CONDENSED STATEMENTS OF OPERATIONS (Unaudited) 2021 2020 2021 2020 For the Three Months Ended For the Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Operating Expenses: Selling, general and administrative expenses 1,481,972 1,164,089 3,954,174 3,001,720 Research and development expenses 1,224,559 758,198 3,946,070 1,974,995 Loss from Operations ( 2,706,531 ) ( 1,922,287 ) ( 7,900,244 ) ( 4,976,715 ) Other (Income) Expense: Gain on extinguishment of note payable ( 312,700 ) - ( 312,700 ) - Interest (income) expense, net ( 4,522 ) ( 564 ) ( 14,182 ) ( 3,425 ) Change in fair value of derivative liabilities - 53,046 - ( 211,807 ) Other expense - - ( 33,272 ) - Total Other (Income) Expense ( 317,222 ) 52,482 ( 360,154 ) ( 215,232 ) Net Loss ( 2,389,309 ) $ ( 1,974,769 ) $ ( 7,540,090 ) $ ( 4,761,483 ) Deemed dividend to Series C Preferred Stockholders - ( 23,859 ) - ( 23,859 ) Net Loss Attributable to Common Stockholders $ ( 2,389,309 ) $ ( 1,998,628 ) $ ( 7,540,090 ) $ ( 4,785,342 ) Net Loss Per Basic and Diluted Common Share: $ ( 0.26 ) $ ( 1.38 ) $ ( 0.96 ) $ ( 4.70 ) Weighted Average Number of Common Shares Outstanding: Basic and Diluted 9,179,524 1,445,820 7,840,482 1,018,420 See Notes to these Unaudited Condensed Financial Statements 2 ENVVENO MEDICAL CORPORATION f/k/a HANCOCK JAFFE LABORATORIES, INC. CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIENCY) (Unaudited) Series C Convertible Additional Total Preferred Stock Common Stock Paid-in Accumulated Stockholders’ Shares Amount Shares Amount Capital Deficit Equity Balance at January 1, 2021 - - 2,541,529 $ 25 $ 72,421,242 $ ( 65,323,411 ) $ 7,097,856 Common stock issued in at the market transactions Common stock issued in at the market transactions, shares Common stock issued in registered direct offering Common stock issued in registered direct offering, shares Common stock issued in public offering - - 5,914,284 59 38,127,717 - 38,127,776 Preferred stock issued in private placement Preferred stock issued in private placement, shares Warrant Exercised Warrant Exercised, shares Common stock issued for exercise of warrants 52,077 1 239,999 - 240,000 Common stock issued in private placement offering Common stock issued in private placement offering, shares Reclassification of Warrant Derivatives to Equity Shared-Based Compensation - - 106,850 - 106,850 Warrants granted to consultants Shares issued in satisfaction of trade payable Shares issued in satisfaction of trade payable, shares Fair Value of Warrants Issued - - 211,976 - 211,976 Net loss - - - ( 2,772,886 ) ( 2,772,886 ) Balance at March 31, 2021 - - 8,507,890 $ 85 $ 111,107,784 $ ( 68,096,297 ) $ 43,011,572 Shared-Based Compensation - - 202,983 - 202,983 Shares issued in satisfaction of trade payable - 5,772 - 37,576 - 37,576 Net loss - - - ( 2,377,895 ) ( 2,377,895 ) Balance at June 30, 2021 - - 8,513,662 85 111,348,343 ( 70,474,192 ) 40,874,236 Common stock issued in at the market transactions 170,963 2 970,573 - 970,575 Common stock issued in registered direct offering 781,615 8 18,273,583 18,273,591 Shared-Based Compensation - - - - 325,002 - 325,002 Net loss - - - ( 2,389,309 ) ( 2,389,309 ) Balance at September 30, 2021 - - 9,466,240 95 130,917,501 ( 72,863,501 ) 58,054,095 Series C Convertible Additional Total Preferred Stock Common Stock Paid-in Accumulated Stockholders Shares Amount Shares Amount Capital Deficit Equity Balance at January 1, 2020 - - 717,274 $ 7 $ 57,177,858 $ ( 56,187,925 ) $ 989,940 Common stock issued in private placement offering - - 52,000 1 24,304 - 24,305 Share-based compensation: - - - - 116,820 - 116,820 Warrants granted to consultants - - - - 14,070 - 14,070 Net loss - - - - - ( 1,159,758 ) ( 1,159,758 ) Balance at March 31, 2020 - - 769,274 $ 8 $ 57,333,052 $ ( 57,347,683 ) $ ( 14,623 ) Common stock issued in public offering - - 192,688 2 1,973,306 - 1,973,308 Share-Based Compensation - - - - 37,717 - 37,717 Net loss - - - - - ( 1,626,956 ) ( 1,626,956 ) Balance at June 30, 2020 - - 961,962 $ 10 $ 59,344,075 $ ( 58,974,639 ) $ 369,446 Common stock issued in public offering - - 575,000 6 3,881,901 - 3,881,907 Preferred stock issued in private placement 4,205,406 42 - 1,358,060 - 1,358,102 Warrant Exercised - - 72,747 1 631,625 - 631,626 Reclassification of Warrant Derivatives to Equity - - - - 334,229 - 334,229 Share-Based Compensation - - - - 194,420 - 194,420 Net loss - - - - - ( 1,974,769 ) ( 1,974,769 ) Balance at September 30, 2020 4,205,406 $ 42 1,609,709 $ 17 $ 65,744,310 $ ( 60,949,408 ) $ 4,794,961 See Notes to these Unaudited Condensed Financial Statements 3 ENVVENO MEDICAL CORPORATION f/k/a HANCOCK JAFFE LABORATORIES, INC. CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) For the Nine Months Ended September 30, 2021 2020 Cash Flows from Operating Activities Net loss $ ( 7,540,090 ) $ ( 4,761,483 ) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation 656,283 363,027 Depreciation and amortization 103,134 71,252 Amortization of right-of-use assets 228,184 216,741 Gain on extinguishment of note payable ( 312,700 ) - Change in fair value of derivatives - ( 211,807 ) Changes in operating assets and liabilities: Prepaid expenses and other current assets ( 35,579 ) ( 232,006 ) Security deposit and other assets ( 24,650 ) - Accounts payable ( 998,595 ) ( 246,960 ) Accrued expenses and other current liabilities ( 586,797 ) ( 45,766 ) Payments on lease liabilities ( 235,651 ) ( 216,514 ) Total adjustments ( 1,206,371 ) ( 302,033 ) Net Cash Used in Operating Activities ( 8,746,461 ) ( 5,063,516 ) Cash Flows from Investing Activities Purchase of property and equipment ( 303,143 ) ( 152,751 ) Net Cash Used in Investing Activities ( 303,143 ) ( 152,751 ) Cash Flows from Financing Activities Proceeds from private placements of common stock and warrants, net - 570,341 Preferred stock issued in private placement - 1,358,102 Proceeds from shares issued under ATM, net 970,575 - Proceeds from registered direct offering, net 18,273,591 - Proceeds from public offering, net 38,127,776 5,855,215 Proceeds from issuance of note payable - 312,700 Proceeds from Warrant Exercises 240,000 631,626 Net Cash Provided by Financing Activities 57,611,942 8,727,984 Net Increase in Cash, Cash Equivalent, and Restricted Cash 48,562,338 3,511,717 Cash, cash equivalents and restricted cash - Beginning of period 9,334,584 2,117,286 Cash, cash equivalents and restricted cash - End of period $ 57,896,922 $ 5,629,003 See Notes to these Unaudited Condensed Financial Statements 4 ENVVENO MEDICAL CORPORATION f/k/a HANCOCK JAFFE LABORATORIES, INC. CONDENSED STATEMENTS OF CASH FLOWS (Continued) (Unaudited) For the Nine Months Ended September 30, 2021 2020 Supplemental Disclosures of Cash Flow Information: Cash Paid (Received) During the Years For: Interest, net $ ( 14,182 ) $ ( 3,425 ) Non-Cash Financing Activities: Fair value of warrants issued in connection with common stock included in derivative liabilities $ - $ 513,534 Fair value of placement agent warrants issued in connection with common stock included in derivative liabilities $ - $ 32,502 Fair value of common stock issued in satisfaction of trade payable $ 37,576 $ - Fair value of warrants issued $ 211,976 $ - Reclassification of warrant derivatives to equity $ - $ ( 334,229 ) See Notes to these Unaudited Condensed Financial Statements 5 ENVVENO MEDICAL CORPORATION f/k/a HANCOCK JAFFE LABORATORIES, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS (Unaudited) Note 1 – Business Organization and Nature of Operations enVVeno Medical Corporation is a med-tech company focused on improving the standard of care in the treatment of venous disease. We are developing tissue-based solutions that are designed to be life sustaining or life enhancing for patients with deep venous Chronic Venous Insufficiency (CVI). CVI occurs when valves inside of the veins of the leg fail, resulting in insufficient blood being returned to the heart. Our products are being developed to address large unmet medical needs by either offering treatments where none currently exist or by substantially increasing the current standards of care. Our lead product is a porcine based device to be surgically implanted in the deep venous system of the leg, and is called the VenoValve®. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal trial for the purpose of obtaining approval to market and sell the device from the U.S. Food and Drug Administration (“FDA”). Our team of officers and directors has been affiliated with numerous medical devices that have received FDA approval or CE marking and have been commercially successful. We currently lease a 14,507 sq. ft. manufacturing facility in Irvine, California, where we manufacture medical devices for our clinical trials, and which has capacity for commercial manufacturing. On September 21, 2021, we announced that we were changing our name from Hancock Jaffe to enVVeno Medical Corporation and that our development strategy is to focus on the treatment of venous disease. In addition to the VenoValve, we announced that we have begun development of a second device for the treatment of venous disease which we are calling enVVe. In connection with this change in strategy, we indicated that we are deferring further development of the CoreoGraft, which is now outside of our primary focus area. 6 ENVVENO MEDICAL CORPORATION f/k/a HANCOCK JAFFE LABORATORIES, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS (Unaudited) Note 2 – Going Concern and Management’s Liquidity Plan The accompanying unaudited condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Although we expect to continue incurring losses for the foreseeable future, may never earn revenues large enough to support operations, and may need to raise additional capital to sustain operations, pursue product development initiatives, and penetrate markets for the sale of products, Management believes that our capital resources at September 30, 2021, are sufficient to meet our obligations as they become due within one year after the date of this interim filing, and sustain operations. 7 ENVVENO MEDICAL CORPORATION f/k/a HANCOCK JAFFE LABORATORIES, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS (Unaudited) Note 3 – Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed financial statements of the Company as of September 30, 2021 and December 31, 2020, and for the three and nine months ended September 30, 2021 and 2020. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the operating results for the full year. These unaudited condensed financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2020 included in the Company’s Form 10-K filed with the SEC on March 31, 2021. The condensed balance sheet as of December 31, 2020 has been derived from the Company’s audited financial statements. Concentrations The Company maintains cash with major financial institutions. Cash held in United States bank institutions is currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000 at each institution. There was an aggregate uninsured cash balance of $ 57,646,922 as of September 30, 2021. Net Loss per Share The Company computes basic and diluted loss per share by dividing net loss attributable to common stockholders by the weighted average number of common stock outstanding during the period, including warrants exercisable for little or no cash consideration. Basic and diluted net loss per common share are the same since the inclusion of common stock issuable pursuant to the exercise of warrants and options, would have been anti-dilutive. Subsequent Events The Company evaluated events that have occurred after the balance sheet date through the date the financial statements were issued. Based upon the evaluation and transactions, the Company did not identify any other subsequent events that would have required adjustment or disclosure in the financial statements. Recent Accounting Standards In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects of the income tax accounting guidance, including requirements such as tax basis step-up in goodwill obtained in a transaction that is not a business combination, ownership changes in investments, and interim-period accounting for enacted changes in tax law. ASU 2019-12 is effective for public business entities for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. There was not a significant impact to the financial statements from the adoption of this standard. 8 ENVVENO MEDICAL CORPORATION f/k/a HANCOCK JAFFE LABORATORIES, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS (Unaudited) Note 4 – Property and Equipment As of September 30, 2021 and December 31, 2020, property and equipment consist of the following: Schedule of Property and Equipment September 30, December 31, 2021 2020 Laboratory equipment $ 501,346 320,830 Furniture and fixtures 124,093 98,392 Computer software and equipment 124,823 65,078 Leasehold improvements 188,589 158,092 Construction Work in Progress – Software 251,163 244,479 Property and equipment, gross 1,190,014 886,871 Less: accumulated depreciation ( 591,038 ) ( 487,904 ) Property and equipment, net $ 598,976 398,967 Depreciation expense amounted to $ 44,076 and $ 66,857 for the nine months ended September 30, 2021 and 2020, respectively. Depreciation expense is reflected in general and administrative expenses in the accompanying statements of operations. Note 5 – Right-of-Use Assets and Lease Liability On September 20, 2017, the Company renewed its operating lease for its manufacturing facility in Irvine, California, effective October 1, 2017, for five years with an option to extend the lease for an additional 60 -month term at the end of lease term. The initial lease rate was $ 26,838 per month with escalating payments. In connection with the lease, the Company is obligated to pay $ 7,254 monthly for operating expenses for building repairs and maintenance. The Company has no other operating or financing leases with terms greater than 12 months . The Company adopted Accounting Standards Codification (“ASC”) Topic 842, Leases (Topic 842) effective January 1, 2019 using the modified-retrospective method and elected the package of transition practical expedients for expired or existing contracts, which does not require reassessment of previous conclusions related to contracts containing leases, lease classification and initial direct costs, and therefore the comparative periods presented are not adjusted. In addition, the Company elected to adopt the short-term lease exception and not apply Topic 842 to arrangements with lease terms of 12 months or less. On January 1, 2019, upon adoption of Topic 842, the Company recorded right-of-use assets of $ 1,099,400 , lease liabilities of $ 1,121,873 and eliminated deferred rent of $ 22,473 . The Company determined the lease liabilities using the Company’s estimated incremental borrowing rate of 8.5 % to estimate the present value of the remaining monthly lease payments. 9 ENVVENO MEDICAL CORPORATION f/k/a HANCOCK JAFFE LABORATORIES, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS (Unaudited) Our operating lease cost is as follows: Schedule of Operating Lease Cost For the Three Months Ended September 30, For the Nine Months Ended September 30, 2021 2021 Operating lease cost $ 85,492 $ 256,475 Supplemental cash flow information related to our operating lease is as follows: Schedule of Supplemental Cash Flow Information Related to Operating Lease For the Three Months Ended September 30, For the Nine Months Ended September 30, 2021 2021 Operating Cash Flow Information: Cash paid for amounts in the measurement of lease liabilities $ 87,981 $ 263,943 Schedule of Operating Remaining Lease Term and Discount Rate Remaining lease term and discount rate for our operating lease is as follows: September 30, 2021 Remaining lease term 1 year Discount rate 8.5 % Maturity of our lease liabilities by fiscal year for our operating lease is as follows: Schedule of Maturity of Lease Liabilities September 30,2021 Three months ended December 31, 2020 $ 90,618 Year ended December 31, 2021 271,854 Total $ 362,472 Less: Imputed Interest ( 30,175 ) Present value of our lease liability $ 332,297 10 ENVVENO MEDICAL CORPORATION f/k/a HANCOCK JAFFE LABORATORIES, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS (Unaudited) Note 6 – Accrued Expenses and Other Current Liabilities As of September 30, 2021, and December 31, 2020, accrued expenses and other current liabilities consist of the following: Schedule of Accrued Expenses September 30, December 31, 2021 2020 Accrued compensation costs $ 252,374 $ 473,799 Accrued professional fees 82,500 79,650 Accrued franchise taxes 23,770 25,607 Accrued research and development - 368,809 Other accrued expenses - 188,104 Accrued expenses $ 358,644 $ 1,135,969 Note 7 – Note Payable On April 12, 2020, the Company obtained a loan (the “Loan”) in the amount of $ 312,700 , pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act, which was enacted March 27, 2020. The Loan, which was in the form of a Note dated April 12, 2020, was to mature on April 12, 2022 , and bore interest at a rate of 1 % per annum, payable monthly commencing on November 12, 2020. On September 8, 2021, the Company was notified the Loan and any accrued interest had been forgiven. In connection with this, the Company recorded a gain on extinguishment of debt of $ 312,700 . Note 8 – Commitments and Contingencies Litigations Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements. Robert Rankin Complaints On July 9, 2020, the Company was served with a civil complaint filed in the Superior Court for the State of California, County of Orange by a former employee, Robert Rankin, who resigned his employment on or about March 30, 2020. The case is entitled Rankin v. Hancock Jaffe Laboratories, Inc. et al., Case No. 30-2020-01146555-CU-WR-CJC and was filed on May 27, 2020. On September 3, 2020 the Company and its Chief Executive Officer were served with a second complaint filed in the Superior Court for the State of California, County of Orange by Mr. Rankin. The case is entitled Rankin v. Hancock Jaffe Laboratories, Inc. et al., Case No. 30-2020-01157857 and was filed on August 31, 2020. The complaints assert several causes of action including a cause of action for failure to timely pay Mr. Rankin’s accrued and unused vacation and three months’ severance under his July 16, 2018 employment agreement, defamation, unlawful labor code violations, sex-based discrimination, and unfair competition, and seeks damages for lost wages, emotional and mental distress, consequential damages, punitive damages and attorney’s fees and costs. The Company intends to vigorously defend the claims, investigate the allegations, and assert counterclaims. As of the date of these financial statements, the amount of loss associated with these complaints, if any, cannot be reasonably estimated. Accordingly, no amounts related to these complaints are accrued as of September 30, 2021. 11 ENVVENO MEDICAL CORPORATION f/k/a HANCOCK JAFFE LABORATORIES, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS (Unaudited) Note 10 – Stockholders’ Equity Common Stock On February 11, 2021, the Company raised $ 41,400,000 in gross proceeds, with cash offering costs of approximately $ 3,300,000 , in a public offering of 5,914,284 shares of its common stock for a purchase price of $ 7.00 per share and warrants to purchase 2,957,142 shares of its common stock. The exercise price of the warrants is $ 7.00 per share, subject to customary adjustments and they expire on February 11, 2026 . The warrants had grant date fair value of $ 4.84 per share for an aggregate grant date fair value of $ 14,312,567 , using the Black Scholes method with the following assumptions used: stock price of $ 7.53 , risk-free interest rate of 0.11 %, volatility of 113.1 %, annual rate of quarterly dividends of 0 %, and a contractual term of 2.5 years. We determined that equity classification of the warrants was appropriate. Accordingly, their value is included in additional paid-in capital. On April 26, 2021, the Company issued 5,772 shares with a value of $ 6.51 per share, or $ 37,576 , in satisfaction of a trade payable. On August 12, 2021, the Company entered into an At-the-Market Offering Agreement to create an at-the-market equity program under which it may sell up to $ 25,000,000 of shares of the Company’s common stock from time to time. During the quarter ending September 30, 2021, the Company sold 170,963 shares for aggregate net proceeds of approximately $ 971,000 . On September 9, 2021, the Company entered a securities purchase agreement pursuant to which it completed a registered direct offering in which it sold 781,615 shares of common stock and Pre-Funded Warrants to purchase 1,759,035 shares of common stock, for aggregate net proceeds of approximately $ 18,300,000 . We determined that equity classification of the warrants was appropriate. Accordingly, their value is included in additional paid-in capital. In connection with this transaction, the Company also issued to the placement agent as compensation a warrant to purchase up to 152,439 shares of common stock with substantially the same terms as the warrants issued in the registered direct offering. The warrants are exercisable immediately upon issuance, have an initial exercise price of $ 9.84 per share, subject to customary adjustments, and expire in April 2025. Warrants In November 2020 the Company’s Board of Directors approved the issuance of warrants to purchase 6,400 shares of common stock to an advisor and warrants to purchase 20,000 shares of common stock to certain participants in the preferred share exchange. Separately the Company agreed to re-price warrants issued to the placement agent for the Company’s February 25, 2020 private placement. These warrants and the re-priced warrant were issued in February 2021. The value of these warrants when they were issued was $ 211,976 . The Company determined their value using the Black-Scholes method with the following assumptions: stock price of $ 8.91 - $ 9.31 , risk-free interest rate of 0.47 %, volatility of 113 %, annual rate of quarterly dividends of 0 %, and an expected term of 2.5 to 3.5 years. Stock Options From time to time, the Company issues options for the purchase of its common stock to employees and others. Share-based compensation related to stock options is included in selling, general and administrative expenses on the accompanying statement of operations, and was $ 0.6 and $ 0.4 million of during the nine months ended September 30, 2021 and 2020, respectively. As of September 30, 2021, there was $ 1.6 million of unrecognized stock-based compensation expense related to outstanding stock options that will be recognized over the weighted average remaining vesting period of 1.7 years. 12 ENVVENO MEDICAL CORPORATION f/k/a HANCOCK JAFFE LABORATORIES, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS (Unaudited) Note 10 – Net Loss per Share The following table summarizes the number of potentially dilutive common stock equivalents excluded from the calculation of diluted net loss per common share as of September 30, 2021 and 2020: Summary of Potentially Dilutive Common Stock Equivalents Excluded from Diluted Net Loss Per Share September 30, 2021 2020 Shares of common stock issuable upon exercise of warrants 4,554,471 1,360,883 Shares of common stock issuable upon exercise of options 485,212 212,622 Potentially dilutive common stock equivalents excluded from diluted net loss per share 5,039,683 1,573,504 Note 11 – Related Party Transactions On June 8, 2021, the Company updated its agreement with the vendor affiliated by common ownership and control with a shareholder holding approximately 10 % of the Company’s outstanding common stock. The Company engaged this vendor to provide support in the VenoValve U.S. pivotal trial. Expenditures to that vendor were approximately $ 0.6 million during the nine months ending September 30, 2021, and are included in in Research and Development expenses in the accompanying statement of operations. 13 Item 2: MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion should be read in conjunction with our unaudited condensed financial statements and notes thereto included herein. In connection with, and because we desire to take advantage of, the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, we caution readers regarding certain forward-looking statements in the following discussion and elsewhere in this report and in any other statement made by, or on our behalf, whether or not in future filings with the Securities and Exchange Commission. Forward-looking statements are statements not based on historical information and which relate to future operations, strategies, financial results or other developments. Such forward-looking statements involve significant risks and uncertainties. Forward looking statements are necessarily based upon estimates and assumptions that are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control and many of which, with respect to future business decisions, are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward-looking statements made by, or on our behalf. Words such as “anticipate,” “estimate,” “plan,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions are used to identify forward-looking statements. Such forward-looking statements also involve other factors which may cause our actual results, performance or achievements to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this Quarterly Report. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Unless the context requires otherwise, references in this document to “enVVeno” “we”, “our”, “us” or the “Company” are to enVVeno Medical Corporation. Overview enVVeno Medical Corporation is a med-tech company focused on improving the standard of care in the treatment of venous disease. We are developing tissue-based solutions that are designed to be life sustaining or life enhancing for patients with deep venous Chronic Venous Insufficiency (CVI). CVI occurs when valves inside of the veins of the leg fail, resulting in insufficient blood being returned to the heart. Our products are being developed to address large unmet medical needs by either offering treatments where none currently exist or by substantially increasing the current standards of care. Our lead product is a porcine based device to be surgically implanted in the deep venous system of the leg, and is called the VenoValve®. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal trial for the purpose of obtaining approval to market and sell the device from the U.S. Food and Drug Administration (“FDA”). Our team of officers and directors has been affiliated with numerous medical devices that have received FDA approval or CE marking and that have been commercially successful. We currently lease a 14,507 sq. ft. manufacturing facility in Irvine, California, where we manufacture medical devices for our clinical trials, and which has capacity for commercial manufacturing. On September 21, 2021, we announced that we were changing our name from Hancock Jaffe to enVVeno Medical Corporation and that our development strategy is to focus on the treatment of venous disease. In addition to the VenoValve, we announced that we have a second product in the early stages of development called enVVe. In connection with this change in strategy, we indicated that we are deferring further development of the CoreoGraft, which is now outside of our primary focus area. Each of our products will be required to successfully complete significant clinical trials to demonstrate safety and efficacy before it will be able to be approved by the FDA. 14 VenoValve The VenoValve is a porcine based valve developed at enVVeno to be implanted in the deep venous system of the leg to treat severe CVI. By reducing reflux, and lowering venous hypertension, the VenoValve has the potential to reduce or eliminate the symptoms of deep venous, severe CVI, including venous leg ulcers. The current version of the VenoValve is designed to be surgically implanted into the femoral vein of the patient via a 5 to 6 inch incision in the upper thigh. There are presently no FDA approved medical devices to address valvular incompetence, or effective treatments for deep venous CVI. Current treatment options include compression garments, or constant leg elevation. These treatments are generally ineffective, as they attempt to alleviate the symptoms of CVI without addressing the underlying causes of the disease. In addition, we believe compliance with compression garments and leg elevation is extremely low, especially among the elderly. The premise behind the VenoValve is that by reducing the underlying causes of CVI, reflux and venous hypertension, the debilitating symptoms of CVI will decrease, resulting in improvement in the quality of the lives of CVI sufferers. We estimate that there are approximately 2.4 million people in the U.S. that suffer from deep venous CVI due to valvular incompetence. VenoValve Clinical Status After consultation with the FDA, and as a precursor to the U.S. pivotal trial, we conducted a small first-in-human study for the VenoValve in Colombia. The first-in-human trial included eleven (11) patients. In addition to providing safety and efficacy data, the purpose of the first-in-human study was to provide proof of concept, and to provide valuable feedback to make any necessary product modifications or adjustments to our surgical implantation procedures for the VenoValve prior to conducting the U.S. pivotal trial. Endpoints for the VenoValve first-in-human study include safety (device related adverse events), reflux, measured by doppler, a VCSS score used by the clinician to measure disease severity, and a VAS score used by the patient to measure pain, and a quality of life measurement. Final results from the one (1) year first-in-human study were presented at the Charing Cross International Symposium in April of 2021. Among the eleven (11) patients in the study, reflux improved an average of 54%, Venous Clinical Severity Scores (“VCSSs”) improved an average of 56%, and visual analog scale (VAS) scores, which are used by patients to measure pain, improved an average of 76%, all at one (1) year when compared to pre-surgery levels. VCSS scores are commonly used by clinicians in practice and in clinical trials to objectively assess outcomes in the treatment of venous disease, and include ten characteristics including pain, inflammation, skin changes such as pigmentation and induration, the number of active ulcers, and ulcer duration. The improvement in VCSS scores is significant and indicates the VenoValve patients who had severe CVI pre-surgery, had mild CVI or the complete absence of disease at one-year post surgery. Quality of life measured by a VEINES score showed statistically significant improvement. 15 VenoValve safety incidences during the one (1) year first-in-human study were minor with no reported device related adverse events. Minor non-device related adverse safety issues included one (1) fluid pocket (which was aspirated), intolerance from Coumadin anticoagulation therapy, three (3) minor wound infections (treated with antibiotics), and one occlusion due to patient non-compliance with anti-coagulation therapy. In preparation for the VenoValve U.S. pivotal trial, on March 5, 2021, we submitted an IDE application with the FDA. An investigational device exemption or IDE from the FDA is required before a medical device company can proceed with a pivotal trial for a class III medical device. On April 1, 2021, twenty-seven days after filing the IDE application, we received notification from the FDA that our IDE application was approved. We have named the U.S. pivotal for the VenoValve the SAVVE (Surgical Anti-reflux Veno Valve Endoprosthesis) study. It is a prospective, non-blinded, single arm, multi-center study of seventy-five (75) CVI patients to be enrolled at up to 20 U.S. sites. No product modifications for the VenoValve were necessary following the first-in-human study and the SAVVE trial will evaluate the same device that was used in the first-in-human study. Endpoints for the SAVVE trial mirror those endpoints used for the first-in-human trial. The primary safety endpoint for the pivotal trial is the absence of material adverse safety events (mortality, deep wound infection, major bleeding, ipsilateral deep vein thrombosis, pulmonary embolism) in twenty six percent (26%) or less of the patients at one (1) month post implantation, and the primary effectiveness endpoint for the pivotal trial is improvement in reflux of at least thirty percent (30%), measured at six (6) months post VenoValve implantation. In the first-in-human study there were no reported material adverse safety events at one (1) month post implantation, and reflux improved an average of fifty six percent (56%) at six (6) months post implantation. VCSS scoring to measure disease manifestations, VAS scores to measure pain, and quality of life measurements will also be monitored in the study. On August 3, 2020, we announced that the FDA granted Breakthrough Device Designation status to the VenoValve. The FDA’s Breakthrough Devices Program was established to enable priority review for devices that provide more effective treatment or diagnosis of life threatening or irreversibly debilitating diseases or conditions. The goal of the FDA’s Breakthrough Devices Program is to provide patients and health care providers with timely access to medical devices by speeding up their development, assessment, and review, while preserving the FDA’s mission to protect and promote public health. At the end of the VenoValve first-in-human study, we asked the study participants if we could continue to monitor them for an additional one (1) year period. Eight patients agreed to be monitored and in August of 2021, two (2) year follow-up data was presented at the Society of Vascular Surgery Conference in San Diego, for the cohort of eight (8) patients. That data indicated no recurrences of the severe CVI that was present pre-VenoValve, including no ulcer recurrences for those patients whose venous ulcers had healed following VenoValve surgery. There were no reported safety issues from the end of one (1) year first-in-human study to the end of the two (2) year reporting period. In October of 2021, we announced that the first patient in the SAVVE pivotal trial underwent successful VenoValve implantation surgery and had been discharged from the hospital. The surgery was performed by Dr. Adriana Laser, associate professor of surgery at Albany Medical College and a vascular surgeon with Albany Med Vascular Surgery. At the time of the first implantation, we had five (5) clinical sites that are actively enrolling patients in the SAVVE study and additional sites will become active on a rolling basis over the next several weeks. 16 Comparison of the three months ended September 30, 2021 and 2020 Overview We reported net losses of $2.4 million and $2.0 million for the three months ended September 30, 2021 and 2020, respectively, representing an increase in net loss of $0.4 million or 21%, due to an increase in operating expenses of $0.8 million, and a net increase in other income and expense of $0.4 million. Revenues As a developmental stage Company, our revenue, if any, is expected to be diminutive and dependent on our ability to commercialize our product candidates. Selling, General and Administrative Expenses For the three months ended September 30, 2021, selling, general and administrative expenses increased by $0.3 million or 27%, to $1.5 million from $1.2 million for the three months ended September 30, 2020. The net increase reflects increases of $0.2 million in compensation due to higher share-based compensation in 2021, $0.1 million in outside services related to human resources and information technology support fees which were higher primarily because of increases in personnel, $0.1 million in higher insurance and other office expense due to higher D&O insurance premiums, travel, and cleaning, all mainly due to increases in personnel and returning to full time use of the office in the 2021 period. These increases were partially offset by lower legal expenses, which were $0.1 million lower in 2021 because of the resolution of a number of legal matters during 2020. Research and Development Expenses For the three months ended September 30, 2021, research and development expenses increased by $0.5 million or 62%, to $1.2 million from $0.8 million for the three months ended September 30, 2020. The increase is primarily due to increases of $0.3 million in compensation and related costs due to a larger team in 2021, and $0.1 million in higher consulting costs and $0.1 million in lab testing, both related to preparations for SAVVE. Gain on Extinguishment of Note Payable For the quarter ended September 30, 2021 the Company recorded a one-time $0.3 million gain on extinguishment of note payable due to the forgiveness of the loan it had obtained under the PPP program authorized by the CARES act. Change in Fair Value of Derivative Liability For the quarter ended September 30, 2020, we recorded a loss on the change in fair value of derivative liabilities of $0.1 million. Our derivative liabilities were related to warrants issued in connection with our Bridge Offering in February 2020. There were no similar instruments outstanding during the quarter ended September 30, 2021. Comparison of the nine months ended September 30, 2021 and 2020 Overview We reported net losses of $7.5 million and $4.8 million for the nine months ended September 30, 2021 and 2020, respectively, representing an increase in net loss of $2.8 million, or 58%, due to an increase in operating expenses of $2.9 million, and an increase in other income and expense of $0.1 million. Revenues As a developmental stage Company, our revenue, if any, is expected to be diminutive and dependent on our ability to commercialize our product candidates. 17 Selling, General and Administrative Expenses For the nine months ended September 30, 2021, selling, general and administrative expenses increased by $1.0 million or 32%, to $4.0 million from $3.0 million the nine months ended September 30, 2020. The increase is primarily due to increases of approximately $0.3 million in stock-based compensation expense, $0.3 million in other compensation primarily from the additional personnel and directors’ cash compensation in 2021, $0.3 million in other administrative expenses due to higher Delaware franchise tax resulting from changes in the Company’s capital structure, and increases in cleaning and other office related expenses due to returning to full time use of the office in the 2021 period, $0.1 million in higher insurance due to higher D&O insurance premiums, and $0.1 million increase in outside services related to the Company’s increased investor outreach in 2021. These increases were partially offset by lower legal expenses, which were $0.1 million lower in 2021 because of the resolution of a number of legal matters during 2020. Research and Development Expenses For the nine months ended September 30, 2021, research and development expenses increased by $2.0 million or 100%, to $4.0 million from $2.0 million for the nine months ended September 30, 2020. The increase is due to expanded activity related to SAVVE and includes $0.8 million in higher compensation from additional personnel, $0.5 million in consulting costs for SAVVE, $0.4 million for testing related to FDA submissions and SAVVE preparation, and $0.3 million in lab supplies and other related lab costs to support those activities. Change in Fair Value of Derivative Liability For the nine months ended September 30, 2020, we recorded a gain on the change in fair value of derivative liabilities of $0.2 million. Our derivative liabilities were related to warrants issued in connection with our Bridge Offering in February 2020. There were no similar instruments outstanding during the period ended September 30, 2021. Gain on Extinguishment of Note Payable For the nine months ended September 30, 2021 the Company recorded a $0.3 million gain on extinguishment of note payable due to the forgiveness of the loan it had obtained under the PPP program authorized by the CARES act. Liquidity and Capital Resources We have incurred losses since inception and negative cash flows from operating activities for the nine months ended September 30, 2021. Since inception, we have funded our operations primarily through our public and private offerings of equity and private placement of convertible debt securities as well as modest revenues from royalties, contract research and sales of the ProCol Vascular Bioprosthesis. As of November 8, 2021, we had a cash balance of approximately $56,900,000. We measure our liquidity in a variety of ways, including the following: September 30 2021 December 31, 2020 (unaudited) Cash $ 57,896,922 $ 9,334,584 Working capital $ 57,088,836 $ 6,382,818 Based upon our cash and working capital as of September 30, 2021, we have sufficient cash to sustain the Company’s operations at least one year after the date of this Report. We have historically funded our operations through public and private issuances of debt and equity. Our current cash on hand is the result equity issuances completed in February and September of this year. We expect to use this cash to fund continued research and trials for our products such as the SAVVE for our VenoValve. If our trials are successful, we believe it may be necessary to raise additional capital to take our products to market. If this is necessary, we believe the Company could have access to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means. However, there can be no assurance the Company will be able to raise additional capital or obtain new financing when needed on commercially acceptable terms, if at all. The COVID-19 pandemic has disrupted the global economy and has negatively impacted large populations including people and businesses that may be directly or indirectly involved with the operation of our Company and the manufacturing, development, and testing of our product candidates. The full scope and economic impact of COVID-19 is still unknown and there are many risks from the COVID-19 that could generally and negatively impact economies and healthcare providers in the countries where we do business, the medical device industry as a whole, and development stage, pre-revenue companies such as enVVeno. Off-Balance Sheet Arrangements None. Contractual Obligations As a smaller reporting company, we are not required to provide the information requested by paragraph (a)(5) of this Item. Critical Accounting Policies and Estimates For a description of our critical accounting policies, see Note 4 – Significant Accounting Policies in Part 1, Item 1 of this Quarterly Report on Form 10-Q. 18 Item 3. Quantitative and Qualitative Disclosure About Market Risk As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item. Item 4: Controls and Procedures Disclosure Controls and Procedures Our management carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer (who is our Principal Executive Officer) and our Chief Financial Officer (who is our Principal Financial Officer and Principal Accounting Officer), of the effectiveness of the design of our disclosure controls and procedures (as defined by Exchange Act Rules 13a-15(e) or 15d-15(e)) as of September 30, 2021, pursuant to Exchange Act Rule 13a-15(b). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of September 30, 2021 because of the material weakness in internal control over financial reporting discussed below. Notwithstanding the material weakness in internal control over financial reporting described below, our management has concluded that our consolidated financial statements included in the Quarterly Report on Form 10-Q are fairly stated in all material respects in accordance with accounting principles generally accepted in the United States of America. Material Weakness A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. We did not maintain effective controls over accounting for warrants issued in connection with our February 25, 2020 financing, and, as a result, did not record an associated derivative liability on a timely basis. At the time of issuance, the Company sought and received technical accounting guidance on the accounting treatment for the derivative liability. However, due to personnel changes, the existence of the guidance was not known to new finance personnel. This deficiency did not result in the revision of any of our previously issued financial statements. However, if not addressed, the deficiency could result in material misstatement in the future. Accordingly, our management has determined that this control deficiency constitutes a material weakness. Remediation Plan We are in the process of developing a detailed plan for remediation of the material weakness, including developing and maintaining a transition process for new finance executives to review existing critical accounting policies and judgments. We will continue to assess the effectiveness of our remediation efforts in connection with our future assessments of the effectiveness of internal control over financial reporting and disclosure controls and procedures. Changes in Internal Control over Financial Reporting Other than the material weakness discussed above, there was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) identified in connection with the evaluation of our internal control that occurred during the quarter ended September 30, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Inherent Limitations of Controls Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. Controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or deterioration in the degree of compliance with the policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. 19 PART II - OTHER INFORMATION Item 1. Legal Proceedings From time to time we may be subject to litigation and arbitration claims incidental to its business. Such claims may not be covered by our insurance coverage, and even if they are, if claims against us are successful, they may exceed the limits of applicable insurance coverage. On July 9, 2020, the Company was served with a civil complaint filed in the Superior Court for the State of California, County of Orange by a former employee, Robert Rankin, who resigned his employment on or about March 30, 2020. The case is entitled Rankin v. Hancock Jaffe Laboratories, Inc. et al., Case No. 30-2020-01146555-CU-WR-CJC and was filed on May 27, 2020. The complaint asserts several causes of action, including a cause of action for failure to timely pay Mr. Rankin’s accrued and unused vacation and three months’ severance under his July 16, 2018 employment agreement with the Company. Mr. Rankin alleges that he was forced to resign, however, we believe that he did not give the Company notice or an opportunity to cure the allegations. The complaint seeks, inter alia, back pay, unpaid wages, compensatory damages, punitive damages, attorneys’ fees, and costs. On September 3, 2020 the Company and its Chief Executive Officer were served with a second complaint filed in the Superior Court for the State of California, County of Orange by Mr. Rankin. The case is entitled Rankin v. Hancock Jaffe Laboratories, Inc. et al., Case No. 30-2020-01157857 and was filed on August 31, 2020. The complaint asserts several causes of action, including defamation, unlawful labor code violations, sex-based discrimination, unfair competition, and seeks damages for lost wages, emotional and mental distress, consequential damages, punitive damages and attorney’s fees and costs. The Company intends to vigorously defend the claims, investigate the allegations, and assert counterclaims. Mr. Rankin resigned as the Company’s Chief Financial Officer, Secretary and Treasurer on March 30, 2020. Item 1A. Risk Factors As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item. However, in addition to our current risk factors are set forth in our Form 10-K, filed with the SEC on March 31, 2021, we have also identified the following additional risks to our company. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds None. Item 3. Defaults upon Senior Securities None. Item 4. Mine and Safety Disclosure Not applicable. Item 5. Other Information None. 20 Item 6. Exhibits The following is a complete list of exhibits filed as part of this Form 10-Q. Exhibit numbers correspond to the numbers in the Exhibit Table of Item 601 of Regulation S-K. Exhibit Description 31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act. * 31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Sarbanes-Oxley Act. * 32 Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act** 101.INS Inline XBRL Instance Document* 101.SCH Inline XBRL Taxonomy Extension Schema Document* 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document* 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document* 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document* 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith. ** Furnished and not filed herewith. 21 SIGNATURES Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: November 10, 2021 ENVVENO MEDICAL CORPORATION By: /s/ Robert Berman Robert Berman Chief Executive Officer (Principal Executive Officer) By: /s/ Craig Glynn Craig Glynn Chief Financial Officer (Principal Financing and Accounting Officer) 22